Pfizer Q3 profit beats estimates; oncology drugs shine
Oct 29 (Reuters) - Pfizer Inc reported better-than-expected third-quarter earnings on Tuesday, helped by costs cuts and growing sales of recently approved cancer medicines.
The largest U.S. drugmaker said it earned $2.59 billion, or 39 cents per share, in the quarter, compared with $3.21 billion, or 43 cents per share, in the year-earlier period.
Excluding special items, Pfizer earned 58 cents per share. Analysts, on average, expected 56 cents per share, according to Thomson Reuters I/B/E/S.
- Housing, jobs data weaken, but overall economic picture still upbeat
- Last-minute Obamacare exemption for those with canceled plans
- Target cyber breach hits 40 million payment cards at holiday peak |
- New York Mayor-elect's reputation for lateness parodied on Twitter
- U.S. diplomats, but not prosecutors, seek to quell India dispute |